Opus Genetics, Inc.
IRD- 1D
- -3.3%
Opus Genetics, Inc. in brief
Opus Genetics, Inc. is a listed company in the Biotechnology industry, based in the USA. Its market value was $396 M on 15 October 2026, which makes it the 13,589th largest listed company in the world and the 2,674th largest in the USA on this site. In the year to December 2025 it had sales of $14 M and a net loss of $50 M. It employs about 27 people. Its shares trade under the symbol IRD (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Opus Genetics, Inc.
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases, and other types of therapies for additional ophthalmic disorders.
In November 2020, Ocuphire Pharma, Inc. completed a reverse merger into Rexahn Pharmaceuticals, Inc., a publicly traded company that had ceased its business of drug development activities, and simultaneously raised just over $21 million through an offering of common shares and warrants to purchase common shares. The combined company continued to operate under the name of Ocuphire Pharma, Inc.
Opus Genetics, Inc. timeline
- 2003
- ✎Renamed Corporate Road Show Dot Com IncFormerly Ferraro Frank.
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2005
- ✎Renamed Rexahn Pharmaceuticals, Inc.Formerly Corporate Road Show Dot Com Inc.
- 2020
- ✎Renamed Ocuphire Pharma, Inc.Formerly Rexahn Pharmaceuticals, Inc..
- 2022
- 💰Record revenue of $40 millionFY2022, the highest of the 6 years on record.
- 2024
- ✎Renamed Opus Genetics, Inc.Formerly Ocuphire Pharma, Inc..
Events of Opus Genetics, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,723 (Jan 2020) · #2,668 (Oct 2026) · #2,677 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 50.0×
- Price / book
- 25.8×
- Free cash flow yield
- -1.7%
- Net margin (TTM)
- -1723.5%
- Operating margin
- -271.8%
- Return on equity
- -890.4%
- Liabilities / assets
- 69.5%
- Net debt
- $-44M
- Revenue growth
- +29.2%
- R&D / revenue
- 217.0%
- Revenue per employee
- $526 K
- Profit per employee
- $-1.8 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $14M | +29.2% | $-39M | $-50M | -349.2% |
| Dec 2024 | $11M | -42.3% | $-62M | $-58M | -523.5% |
| Dec 2023 | $19M | -52.2% | $-11M | $-10M | -52.4% |
| Dec 2022 | $40M | +6654.2% | $18M | $18M | 44.9% |
| Dec 2021 | $1M | — | $-23M | $-57M | -9608.5% |
| Dec 2020 | — | — | $-20M | $-25M | — |
| Dec 2019 | $3M | — | $-4M | $-6M | -205.7% |
| Dec 2018 | — | — | $-21M | $-14M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-35M | — | — | $-0.80 | — |
| Dec 2024 | $-26M | — | — | $-2.15 | — |
| Dec 2023 | $-1M | — | — | $-0.46 | — |
| Dec 2022 | $14M | — | — | $0.87 | — |
| Dec 2021 | $-19M | — | — | $-3.82 | — |
| Dec 2020 | $-7M | $0M | $-7M | $-5.28 | — |
| Dec 2019 | $-4M | $0M | $-4M | $-2.17 | — |
| Dec 2018 | $-19M | — | — | $-5.25 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $1M (-63.0% on a year earlier), net income $-47M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations
- Oct 21, 20268-KCurrent reportDirectors or officers changed
- Oct 15, 20268-KCurrent reportRegulation FD disclosure
- Sep 11, 20268-KCurrent reportRegulation FD disclosure
- Sep 9, 20268-KCurrent reportRegulation FD disclosure · Other events
- Aug 6, 202610-QQuarterly report · period to Jun 2026
- Aug 6, 20268-KCurrent reportResults of operations
- Jun 16, 20268-KCurrent reportRegulation FD disclosure
- Jun 16, 20268-KCurrent reportRegulation FD disclosure
- May 12, 202610-QQuarterly report · period to Mar 2026
- May 12, 20268-KCurrent reportResults of operations
Official filings of Opus Genetics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $14 M
- Operating income
- $-39 M
- Net income
- $-50 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $50 M
- Total liabilities
- $35 M
- Total equity
- $15 M
As of December-2025
Top 100 institutional investors in Opus Genetics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Perceptive Advisors LLC | 9,000,000 | New | 9.31% | $44 M | Nov 16, 2026 |
| 2 | Caligan Partners LP | 5,960,972 | -116,112 (-1.91%) | 6.17% | $29 M | Nov 16, 2026 |
| 3 | Cormorant Asset Management, LP | 5,500,000 | New | 5.69% | $27 M | Nov 16, 2026 |
| 4 | BlackRock, Inc. | 5,236,178 | +2,119,691 (+68.02%) | 5.42% | $25 M | Nov 13, 2026 |
| 5 | Nantahala Capital Management, LLC | 4,569,528 | -1,553,190 (-25.37%) | 4.73% | $22 M | Nov 13, 2026 |
| 6 | Boxer Capital Management, LLC | 4,533,660 | +1,718,660 (+61.05%) | 4.69% | $22 M | Nov 16, 2026 |
| 7 | Balyasny Asset Management L.P. | 3,728,638 | +640,772 (+20.75%) | 3.86% | $18 M | Nov 16, 2026 |
| 8 | BIOS Capital Management, LP | 3,683,429 | 0 (0.00%) | 3.81% | $18 M | Nov 13, 2026 |
| 9 | Vanguard Capital Management LLC | 3,273,451 | +314,768 (+10.64%) | 3.39% | $16 M | Nov 13, 2026 |
| 10 | Marshall Wace, LLP | 3,161,606 | +1,215,997 (+62.50%) | 3.27% | $15 M | Nov 13, 2026 |
| 11 | Millennium Management LLC | 3,136,021 | +833,920 (+36.22%) | 3.24% | $15 M | Nov 16, 2026 |
| 12 | Trails Edge Capital Partners, LP | 2,411,657 | -332,001 (-12.10%) | 2.50% | $12 M | Nov 16, 2026 |
| 13 | Adage Capital Partners GP, L.L.C. | 2,254,996 | -3,774,779 (-62.60%) | 2.33% | $11 M | Nov 16, 2026 |
| 14 | Geode Capital Management, LLC | 1,810,968 | +443,256 (+32.41%) | 1.87% | $9 M | Nov 6, 2026 |
| 15 | ADAR1 Capital Management, LLC | 1,783,781 | 0 (0.00%) | 1.85% | $9 M | Nov 16, 2026 |
| 16 | State Street Corp | 1,330,398 | +540,262 (+68.38%) | 1.38% | $6 M | Nov 12, 2026 |
| 17 | Boothbay Fund Management, LLC | 1,166,787 | -22,728 (-1.91%) | 1.21% | $6 M | Nov 16, 2026 |
| 18 | AWM Investment Company, Inc. | 1,051,936 | +819,346 (+352.27%) | 1.09% | $5 M | Nov 13, 2026 |
| 19 | Logos Global Management LP | 1,000,000 | New | 1.03% | $5 M | Nov 16, 2026 |
| 20 | Blue Owl Capital Holdings LP | 969,605 | New | 1.00% | $5 M | Nov 13, 2026 |
| 21 | Affinity Asset Advisors, LLC | 900,000 | New | 0.93% | $4 M | Nov 13, 2026 |
| 22 | Goldman Sachs Group Inc | 877,876 | -649,353 (-42.52%) | 0.91% | $4 M | Nov 16, 2026 |
| 23 | Great Point Partners LLC | 776,881 | -1,193,306 (-60.57%) | 0.80% | $4 M | Nov 16, 2026 |
| 24 | Opaleye Management Inc. | 750,000 | -375,000 (-33.33%) | 0.78% | $4 M | Nov 16, 2026 |
| 25 | Vanguard Portfolio Management LLC | 734,419 | +362,469 (+97.45%) | 0.76% | $4 M | Nov 13, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | UBS Group AG | 723,459 | +39,564 (+5.79%) | 0.75% | $4 M | Nov 10, 2026 |
| 27 | Woodline Partners LP | 661,729 | -772,984 (-53.88%) | 0.68% | $3 M | Nov 16, 2026 |
| 28 | Northern Trust Corp | 560,304 | +118,150 (+26.72%) | 0.58% | $3 M | Nov 16, 2026 |
| 29 | Vanguard Fiduciary Trust Co | 538,986 | +128,611 (+31.34%) | 0.56% | $3 M | Nov 13, 2026 |
| 30 | Acuta Capital Partners, LLC | 514,110 | New | 0.53% | $2 M | Nov 16, 2026 |
| 31 | Citadel Advisors LLC | 497,481 | -168,181 (-25.27%) | 0.51% | $2 M | Nov 16, 2026 |
| 32 | Squarepoint Ops LLC | 352,924 | +22,141 (+6.69%) | 0.37% | $2 M | Nov 9, 2026 |
| 33 | Susquehanna International Group, LLP | 350,141 | +153,244 (+77.83%) | 0.36% | $2 M | Nov 16, 2026 |
| 34 | XTX Topco Ltd | 287,409 | +143,314 (+99.46%) | 0.30% | $1 M | Nov 16, 2026 |
| 35 | Propel Bio Management, LLC | 270,036 | New | 0.28% | $1 M | Nov 13, 2026 |
| 36 | Aureus Asset Management, LLC | 265,729 | +207,529 (+356.58%) | 0.27% | $1 M | Nov 13, 2026 |
| 37 | Bleichroeder LP | 236,842 | -500,000 (-67.86%) | 0.24% | $1 M | Nov 13, 2026 |
| 38 | Charles Schwab Investment Management Inc | 204,178 | +39,125 (+23.70%) | 0.21% | $1 M | Nov 16, 2026 |
| 39 | Morgan Stanley | 162,665 | -302,235 (-65.01%) | 0.17% | $1 M | Nov 13, 2026 |
| 40 | Bank of New York Mellon Corp | 151,289 | +28,810 (+23.52%) | 0.16% | $1 M | Nov 5, 2026 |
| 41 | Informed Momentum Co LLC | 145,687 | New | 0.15% | $1 M | Nov 16, 2026 |
| 42 | Two Sigma Investments, LP | 133,632 | -120,330 (-47.38%) | 0.14% | $1 M | Nov 16, 2026 |
| 43 | FMR LLC | 129,404 | +129,262 (+91029.58%) | 0.13% | $1 M | Nov 10, 2026 |
| 44 | Creative Planning | 128,869 | +503 (+0.39%) | 0.13% | $1 M | Nov 2, 2026 |
| 45 | AQR Capital Management LLC | 120,630 | New | 0.12% | $1 M | Nov 16, 2026 |
| 46 | Texas Capital Bank Wealth Management Services Inc | 117,000 | -5,529 (-4.51%) | 0.12% | $1 M | Nov 9, 2026 |
| 47 | Nuveen, LLC | 115,361 | +44,018 (+61.70%) | 0.12% | $1 M | Nov 10, 2026 |
| 48 | Bank Of America Corp /de/ | 108,949 | +53,944 (+98.07%) | 0.11% | $1 M | Nov 16, 2026 |
| 49 | SEI Investments Co | 105,414 | New | 0.11% | $1 M | Nov 10, 2026 |
| 50 | Stonepine Capital Management, LLC | 98,147 | -2,571 (-2.55%) | 0.10% | $0 M | Nov 13, 2026 |
| 51 | Citigroup Inc | 81,718 | +51,626 (+171.56%) | 0.08% | $0 M | Nov 4, 2026 |
| 52 | Rhumbline Advisers | 69,919 | +18,455 (+35.86%) | 0.07% | $0 M | Nov 10, 2026 |
| 53 | Palogic Value Management, L.P. | 65,088 | -65,088 (-50.00%) | 0.07% | $0 M | Nov 16, 2026 |
| 54 | Vanguard Global Advisers, LLC | 64,274 | +49,932 (+348.15%) | 0.07% | $0 M | Nov 13, 2026 |
| 55 | Invesco Ltd. | 63,230 | +9,999 (+18.78%) | 0.07% | $0 M | Nov 12, 2026 |
| 56 | Regency Capital Management Inc.\DE | 61,000 | +3,000 (+5.17%) | 0.06% | $0 M | Nov 9, 2026 |
| 57 | Deutsche Bank AG\ | 59,638 | +6,326 (+11.87%) | 0.06% | $0 M | Nov 6, 2026 |
| 58 | Price T Rowe Associates Inc /MD/ | 57,389 | +13,452 (+30.62%) | 0.06% | $0 M | Nov 16, 2026 |
| 59 | Quadrature Capital Ltd | 41,661 | -4,728 (-10.19%) | 0.04% | $0 M | Nov 13, 2026 |
| 60 | Jpmorgan Chase & Co | 40,507 | +18,308 (+82.47%) | 0.04% | $0 M | Nov 12, 2026 |
| 61 | MetLife Investment Management, LLC | 40,081 | +7,873 (+24.44%) | 0.04% | $0 M | Nov 16, 2026 |
| 62 | Corient Private Wealth LP | 37,624 | New | 0.04% | $0 M | Nov 16, 2026 |
| 63 | Simplex Trading, LLC | 36,204 | +10,651 (+41.68%) | 0.04% | $0 M | Nov 4, 2026 |
| 64 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 33,293 | +8,636 (+35.02%) | 0.03% | $0 M | Nov 16, 2026 |
| 65 | Barclays PLC | 32,160 | +18,803 (+140.77%) | 0.03% | $0 M | Nov 6, 2026 |
| 66 | Captrust Financial Advisors | 32,142 | +142 (+0.44%) | 0.03% | $0 M | Nov 12, 2026 |
| 67 | Miller Financial Services LLC | 30,000 | +3,000 (+11.11%) | 0.03% | $0 M | Oct 20, 2026 |
| 68 | Alliancebernstein L.P. | 25,380 | 0 (0.00%) | 0.03% | $0 M | Nov 16, 2026 |
| 69 | Wells Fargo & Company/mn | 24,936 | -27,697 (-52.62%) | 0.03% | $0 M | Nov 16, 2026 |
| 70 | HighTower Advisors, LLC | 20,500 | New | 0.02% | $0 M | Nov 10, 2026 |
| 71 | Police & Firemen's Retirement System of New Jersey | 19,792 | +3,999 (+25.32%) | 0.02% | $0 M | Nov 9, 2026 |
| 72 | Empirical Financial Services, LLC d.b.a. Empirical Wealth Management | 19,649 | New | 0.02% | $0 M | Oct 27, 2026 |
| 73 | Manufacturers Life Insurance Company, The | 19,205 | +3,256 (+20.42%) | 0.02% | $0 M | Nov 13, 2026 |
| 74 | Raymond James Financial Inc | 16,997 | +1,989 (+13.25%) | 0.02% | $0 M | Nov 12, 2026 |
| 75 | BNP Paribas Financial Markets | 16,981 | +8,800 (+107.57%) | 0.02% | $0 M | Nov 12, 2026 |
| 76 | NewEdge Advisors, LLC | 16,562 | +198 (+1.21%) | 0.02% | $0 M | Nov 13, 2026 |
| 77 | James Investment Research, Inc. | 16,364 | 0 (0.00%) | 0.02% | $0 M | Oct 22, 2026 |
| 78 | StoneX Group Inc. | 15,775 | New | 0.02% | $0 M | Nov 3, 2026 |
| 79 | Centiva Capital, LP | 14,642 | New | 0.02% | $0 M | Nov 13, 2026 |
| 80 | New York State Common Retirement Fund | 14,500 | 0 (0.00%) | 0.01% | $0 M | Nov 17, 2026 |
| 81 | Axq Capital, LP | 13,507 | New | 0.01% | $0 M | Nov 12, 2026 |
| 82 | Voya Investment Management LLC | 13,242 | +2,225 (+20.20%) | 0.01% | $0 M | Nov 10, 2026 |
| 83 | StoneRidge PMG Advisors, LLC | 12,695 | — | 0.01% | $0 M | Nov 4, 2026 |
| 84 | Stokes Family Office, LLC | 12,120 | 0 (0.00%) | 0.01% | $0 M | Nov 12, 2026 |
| 85 | Sanders Morris Harris LLC | 12,000 | New | 0.01% | $0 M | Oct 14, 2026 |
| 86 | Osaic Holdings, Inc. | 11,900 | -2,000 (-14.39%) | 0.01% | $0 M | Nov 12, 2026 |
| 87 | First City Capital Management, Inc. | 11,836 | 0 (0.00%) | 0.01% | $0 M | Oct 27, 2026 |
| 88 | Concurrent Investment Advisors, LLC | 10,002 | New | 0.01% | $0 M | Oct 16, 2026 |
| 89 | Annandale Capital, LLC | 10,000 | 0 (0.00%) | 0.01% | $0 M | Nov 18, 2026 |
| 90 | Seven Fleet Capital Management LP | 10,000 | -133,137 (-93.01%) | 0.01% | $0 M | Nov 16, 2026 |
| 91 | Carolina Wealth Management Inc | 10,000 | 0 (0.00%) | 0.01% | $0 M | Oct 29, 2026 |
| 92 | Legal & General Group Plc | 6,544 | +1,341 (+25.77%) | 0.01% | $0 M | Nov 16, 2026 |
| 93 | State of Wyoming | 6,262 | -9,642 (-60.63%) | 0.01% | $0 M | Oct 28, 2026 |
| 94 | Ameritas Investment Partners, Inc. | 6,205 | +1,345 (+27.67%) | 0.01% | $0 M | Nov 13, 2026 |
| 95 | Hilton Head Capital Partners, LLC | 4,472 | 0 (0.00%) | 0.00% | $0 M | Oct 23, 2026 |
| 96 | Royal Bank Of Canada | 4,417 | +2,322 (+110.84%) | 0.00% | $0 M | Nov 16, 2026 |
| 97 | Russell Investments Group, Ltd. | 4,310 | +28 (+0.65%) | 0.00% | $0 M | Nov 6, 2026 |
| 98 | Farther Finance Advisors, LLC | 4,282 | +792 (+22.69%) | 0.00% | $0 M | Oct 8, 2026 |
| 99 | Quarry LP | 2,988 | +2,486 (+495.22%) | 0.00% | $0 M | Nov 16, 2026 |
| 100 | Sterling Capital Management LLC | 2,296 | +2,108 (+1121.28%) | 0.00% | $0 M | Oct 22, 2026 |
Mutual funds holding Opus Genetics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 2.24 M | $9 M | 2.3% | <0.01% | +18% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 1.35 M | $6 M | 1.4% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 652,278 | $3 M | 0.67% | <0.01% | +38% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 583,651 | $2 M | 0.60% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 502,884 | $2 M | 0.52% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 224,377 | $1 M | 0.23% | <0.01% | −2.1% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 179,782 | $1 M | 0.19% | 0.05% | new | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 130,041 | $0 M | 0.13% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 95,002 | $0 M | 0.10% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 100,099 | $0 M | 0.10% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 66,810 | $0 M | 0.07% | <0.01% | −2.2% | May 31, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 71,343 | $0 M | 0.07% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 58,411 | $0 M | 0.06% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 49,881 | $0 M | 0.05% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 45,672 | $0 M | 0.05% | <0.01% | +53% | May 31, 2026 |
| 🇺🇸 EA Bridgeway Omni Small-Cap Value ETFEmpowered Funds, LLC d/b/a EA Advisers | 42,065 | $0 M | 0.04% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 40,000 | $0 M | 0.04% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 34,934 | $0 M | 0.04% | <0.01% | +33% | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 32,083 | $0 M | 0.03% | <0.01% | −16% | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 35,000 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 24,866 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 23,200 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 25,597 | $0 M | 0.03% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 20,525 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 18,264 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 15,485 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 12,142 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 12,072 | $0 M | 0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 11,996 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 9,817 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 8,460 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 8,460 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 8,420 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 8,183 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 8,074 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 7,308 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 6,884 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 7,624 | $0 M | <0.01% | <0.01% | +28% | Jul 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 6,271 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 4,954 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 4,860 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 4,814 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 4,282 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 4,133 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 4,095 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 2,621 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 1,850 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 1,352 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 1,261 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 13,673 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 5,723 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 621 | $0 M | — | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 52 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Opus Genetics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | George MagrathChief Executive Officer, Director | Sell | -28,258 | $3.899 | $110 K | 2.01 M | Form 4 |
| filed | Joseph K. SchachleChief Operating Officer | Sell | -4,767 | $3.565 | $17 K | 286,673 | Form 4 |
| filed | George MagrathChief Executive Officer, Director | Sell | -9,591 | $3.585 | $34 K | 2.04 M | Form 4 |
| filed | Robert E. GagnonChief Financial Officer | Sell10b5-1 plan | -14,000 | $3.546 | $50 K | 542,375 | Form 4 |
| filed | Benjamin R. YerxaPresident, Director | Sell | -7,669 | $3.551 | $27 K | 696,437 | Form 4 |
| filed | Benjamin R. YerxaPresident, Director | Sell | -25,520 | $3.532 | $90 K | 670,917 | Form 4 |
| filed | Foundation Fighting Blindness Retinal Degeneration FundDirector | Sell | -556,000 | $4.957 | $2.8 M | 3.24 M | Form 4 |
| filed | George MagrathChief Executive Officer, Director | Option exercise | +392,157 | $1.150 | $451 K | 2.12 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Opus Genetics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1.057-for-1 split in the period to ; 1.057-for-1 split ; 1-for-12.05 reverse split ; 1-for-10 reverse split
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q1 2014 | Q1 2014 | $0M |
| Q4 2013 | Q4 2013 | $0M |
| Q3 2013 | Q3 2013 | $0M |
| Q2 2013 | Q2 2013 | $0M |
| Q1 2013 | Q1 2013 | $0M |
| Q4 2012 | Q4 2012 | $0M |
| Q3 2012 | Q3 2012 | $0M |
| Q2 2012 | Q2 2012 | $0M |
| Q1 2012 | Q1 2012 | $0M |
| Q4 2011 | Q4 2011 | $0M |
| Q3 2011 | Q3 2011 | $0M |
| Q2 2011 | Q2 2011 | $0M |
| Q1 2011 | Q1 2012 | $0M |
| Q4 2010 | Q4 2011 | $0M |
| Q3 2010 | Q3 2011 | $0M |
Trading halts
- 2025-06-02 11:55 UTC, code T3, resumed 12:30 UTC
Fails to deliver
- : 179 shares at $4.10
- : 99 shares at $4.24
- : 99 shares at $4.64
- : 4,650 shares at $4.96
- : 3,515 shares at $4.76
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Opus Genetics, Inc. scorecard#
Passes 4 of the 21 checks that could be worked out: strongest in financial health (3 of 5), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 15, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median25.8×Price to book 25.8× against Biotechnology's median of 2.9×.
- ✗Price to sales below its peers' median50.0×Price to sales 50.0× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-1.7%Free cash flow is -1.7% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 5
- ✓Revenue grew in the newest year29.2%Revenue up 29.2% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-29.1%-29.1% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-29.1%-29.1% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-0.80 vs -2.15Diluted EPS -0.80 in fiscal 2025 against -2.15 the year before (report's currency).
- ✗Net income higher than five years earlier-$50 M-$50 M in fiscal 2025 against -$25 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 5
- ✗Profitable in the newest year-$50 MNet income -$50 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-271.8%-271.8% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-449.4%-449.4% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-271.8%-271.8% in fiscal 2025 against 45.7% in 2022.
Financial health3 of 5
- ✓Short-term assets cover short-term liabilities6.4×Current ratio 6.43 at the end of fiscal 2025.
- ✓Debt below equity0.1×Debt to equity 0.07 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $44 M at the end of fiscal 2025.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone0.31Z-score 0.31 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year132.9%Diluted shares up 132.9% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Opus Genetics, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -271.8% | -60.5% | |
| Net margin | -349.2% | -68.9% | |
| Return on equity | -449.4% | -61.0% | |
| Revenue growth, 3 years a year | -29.1% | 12.9% | |
| Revenue growth | 29.2% | 15.8% | |
| Debt to equity | 0.07× | 0.26× |
3of 8on the Piotroski tests of financial strength
- Net loss of $50 million, the 3th loss-making year in a row.
- The share count rose 132.9% in the year.
- More cash than debt: net cash of $44 million.
Opus Genetics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 14+29.1%100% | 11−42.3%100% | 19−52.2%100% | 40+6666%100% | 0.6—100% | 0−100%— | 3.0—100% | — | — | — | |
| Research and development | 31+14.8%217% | 27+52.1%244% | 18+23.0%92.7% | 14−5.4%36.0% | 15+128%2576% | 6.6+21.4%— | 5.5−58.2%183% | 13+22.3%— | 11+6.2%— | 10—— | |
| General and administrative | 22+20.7%155% | 18+52.3%166% | 12+64.5%62.8% | 7.3−10.5%18.2% | 8.1+188%1379% | 2.8+54.8%— | 1.8r5.7−75.5%60.7% | 7.4+11.9%— | 6.6+5.0%— | 6.3—— | |
| Operating expenses | 53−27.7%372% | 73+147%665% | 30+36.9%155% | 22−7.2%54.3% | 23+16.7%3955% | 20+376%— | 4.2r11−79.6%140% | 21+18.3%— | 17+5.7%— | 16—— | |
| Operating income | −39—−272% | −62—−565% | −11−158%−55.5% | 18—45.7% | −23—−3855% | −20—— | −4.2r−11—−140% | −21—— | −17—— | −16—— | |
| Interest and finance income | — | — | — | — | — | — | 0.3+23.3%10.5% | 0.3+22.9%— | 0.2+74.6%— | 0.1—— | |
| Interest expense and finance costs | 0.1—0.9% | 0—0.0% | 0−100%0.0% | 0.0+350%0.0% | 0.0−100.0%0.3% | 6.8+386%— | 1.4—47.0% | — | — | — | |
| Other non-operating income (expense) | 2.0−55.5%14.0% | 4.5+143%40.7% | 1.8—9.6% | −0.0—−0.0% | −0.2−1844%−26.7% | 0.0−99.7%— | 2.6−58.2%86.0% | 6.2—— | −7.9−212%— | 7.1—— | |
| Income before tax | −50—−349% | −58—−523% | −10.0−155%−52.4% | 18—45.7% | −57—−9625% | −25—— | −6.2—−206% | — | — | — | |
| Income tax | 0—0.0% | 0−100%0.0% | 0.0−96.2%0.1% | 0.3—0.8% | 0—0.0% | 0—— | 0—0.0% | — | — | — | |
| Net income attributable to shareholders | −50—−349% | −58—−523% | −10.0−156%−52.4% | 18—44.9% | −57—−9625% | −25—— | −6.2r−8.6—−206% | −14—— | −25—— | −9.3—— | |
| Earnings per share, basic | -0.80—— | -2.15—— | -0.46−151%— | 0.90—— | -3.82—— | -5.28—— | -2.17r-2.18—— | -5.25r-0.44—— | -0.92—— | -0.43r-0.04—— | |
| Earnings per share, diluted | -0.80—— | -2.15—— | -0.46−153%— | 0.87—— | -3.82—— | -5.28—— | -2.17r-2.18—— | -5.25r-0.44—— | -0.92—— | -0.43r-0.04—— | |
| Shares, weighted average (basic) | 62+133%— | 27+23.7%— | 22+8.3%— | 20+34.2%— | 15+219%— | 4.7—— | — | — | — | — | |
| Shares, weighted average (diluted) | 62+133%— | 27+23.7%— | 22+4.8%— | 21+38.7%— | 15+219%— | 4.7+63.8%— | 2.8r4.0+3.9%— | 2.7r33−90.0%— | 27+26.0%— | 22r217—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 45+48.7%89.7% | 30−40.0%82.3% | 51+18.5%93.6% | 43+73.8%87.0% | 25+49.6%94.1% | 16+967%92.7% | 1.5r9.2−82.4%86.2% | 8.7−1.7%54.5% | 8.9−23.1%31.5% | 12—55.0% | |
| Short-term investments | 0−100%0.0% | 0.0−86.7%0.0% | 0.0−69.4%0.0% | 0.0−77.6%0.1% | 0.2—0.8% | 0—0.0% | — | — | — | — | |
| Receivables | 2.0−44.0%4.0% | 3.6+285%9.7% | 0.9−28.7%1.7% | 1.3—2.6% | 0—0.0% | 0—0.0% | — | — | — | — | |
| Other current assets | 1.8+247%3.6% | 0.5+405%1.4% | 0.1+27.5%0.2% | 0.1+12.7%0.2% | 0.1+173%0.3% | 0.0+420%0.1% | 0.0r0.4−99.1%0.3% | 0.6+8.8%3.5% | 0.5+19.0%1.8% | 0.4—2.0% | |
| Current assets | 50+36.7%99.6% | 37−32.1%99.3% | 54+10.1%100% | 49+87.9%100.0% | 26+47.5%100.0% | 18+903%99.9% | 1.8r13−88.9%98.8% | 16−43.5%99.1% | 28+34.5%99.5% | 21—99.4% | |
| Property, plant and equipment | 0.2−21.0%0.4% | 0.3—0.7% | 0−100%0.0% | 0.0−40.0%0.0% | 0.0−28.6%0.0% | 0.0−36.4%0.1% | 0.0r0.1−80.4%1.2% | 0.1−7.4%0.7% | 0.1+37.0%0.4% | 0.1—0.4% | |
| Right-of-use (leased) assets | — | — | — | — | — | — | 0.2—11.4% | — | — | — | |
| Total assets | 50+36.3%100% | 37−31.7%100% | 54+10.1%100% | 49+87.9%100% | 26+47.5%100% | 18+891%100% | 1.8r13−88.9%100% | 16−43.3%100% | 28+34.4%100% | 21—100% | |
| Accounts payable | 3.3+4.6%6.6% | 3.1+46.2%8.5% | 2.2+101%4.0% | 1.1−32.5%2.2% | 1.6+30.5%6.1% | 1.2+255%6.9% | 0.3r1.3−89.2%19.2% | 3.2−2.5%19.7% | 3.2+71.8%11.4% | 1.9—8.9% | |
| Current liabilities | 7.8−31.1%15.5% | 11+179%30.6% | 4.0+46.8%7.5% | 2.8−28.6%5.6% | 3.9+21.0%14.8% | 3.2−65.9%18.0% | 9.3r2.9+196%524% | 3.2—19.7% | — | — | |
| Long-term debt | 1.1—2.2% | 0—0.0% | — | — | — | — | — | — | — | — | |
| Lease liabilities (non-current) | — | — | — | — | — | — | 0.1—3.6% | — | — | — | |
| Total liabilities | 35+209%69.5% | 11+179%30.6% | 4.0+46.8%7.5% | 2.8−28.6%5.6% | 3.9−87.6%14.8% | 31+233%176% | 9.3r3.0+70.5%524% | 5.5−52.4%34.2% | 12+189%40.7% | 4.0—18.9% | |
| Retained earnings | −189—−375% | −139—−377% | −81—−151% | −71—−146% | −89—−343% | −33—−185% | −8.1r−163—−452% | −155—−964% | −140—−496% | −115—−547% | |
| Shareholders' equity | 15+128%30.5% | 6.7−86.5%18.2% | 50+7.9%92.5% | 46+108%94.4% | 22—85.2% | −13—−76.2% | −7.6r10.0—−424% | −1.7r11−110%−10.6% | 17−1.7%59.3% | 17—81.1% | |
| Total liabilities and equity | 50+36.3%100% | 37−31.7%100% | 54+10.1%100% | 49+87.9%100% | 26+47.5%100% | 18+891%100% | 1.8r13−88.9%100% | 16−43.3%100% | 28+34.4%100% | 21—100% | |
| Shares outstanding | 70+121%— | 32+31.7%— | 24+14.9%— | 21+10.7%— | 19+73.2%— | 11+282%— | 2.9r4.0−8.7%— | 3.1r38−90.2%— | 32+33.7%— | 24r237—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | — | — | — | — | — | 0.0−15.0%1.4% | 0.0+13.8%— | 0.0+28.7%— | 0.0—— | |
| Share-based compensation | 3.4+1.1%23.9% | 3.4−4.2%30.6% | 3.5+94.2%18.4% | 1.8−5.6%4.5% | 1.9+27.1%325% | 1.5+389%— | 0.3r0.5−74.9%10.3% | 1.2+17.6%— | 1.0−25.9%— | 1.4—— | |
| Cash from operating activities | −35—−248% | −26—−233% | −1.1−108%−5.8% | 14—35.9% | −19—−3289% | −6.8—— | −3.6r−10—−120% | −19—— | −15—— | −13—— | |
| Capital expenditure | — | — | — | — | — | 0—— | −0.0—−0.8% | — | — | — | |
| Cash from investing activities | 0−100%0.0% | 1.2—11.0% | 0—0.0% | 0—0.0% | −0.1−119%−17.0% | 0.5—— | −0.0r3.1−100%−0.8% | 12—— | −9.4−309%— | 4.5—— | |
| Shares issued | 5.8+29.1%40.9% | 4.5−51.3%40.9% | 9.2+108%48.4% | 4.4−84.5%11.1% | 28—4837% | 0−100%— | 7.7+11.4%255% | 6.9−58.8%— | 17—— | — | |
| Cash from financing activities | 50+1095%352% | 4.2−53.4%38.1% | 9.0+137%47.1% | 3.8−86.3%9.5% | 28+30.7%4687% | 21+349%— | 4.7r7.7−30.5%157% | 6.8−69.4%— | 22+118%— | 10—— | |
| Change in cash | — | — | — | — | — | — | — | −0.2—— | −2.7−294%— | 1.4—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 7.9−45.9%100% | 1.1−63.1%100% | 0.8−73.8%100% | 2.2−50.6%100% | 3.9*−10.2%100% | 3.1−20.4%100% | 2.9+159%100% | 4.4+155%100% | 4.3*+154%100% | 3.9—100% | 1.1—100% | 1.7—100% | 1.7*—100% | |
| Research and development | 47+70.3%590% | 14+126%1275% | 11+86.1%1484% | 11+33.0%490% | 10*+48.3%270% | 6.4−28.6%208% | 6.0−1.1%209% | 8.0+67.5%182% | 7.0*+83.1%164% | 9.0—232% | 6.1—547% | 4.7—278% | 3.8*—227% | |
| General and administrative | 23−6.7%287% | 5.9+18.2%518% | 6.0+4.5%798% | 5.9−6.3%276% | 4.9*−33.0%127% | 5.0+72.1%162% | 5.8+71.9%200% | 6.3+35.9%145% | 7.3*+123%170% | 2.9—74.8% | 3.4—302% | 4.7—273% | 3.3*—194% | |
| Operating expenses | 69−13.0%878% | 20+79.0%1793% | 17+46.2%2283% | 17+15.5%766% | 15*−63.8%396% | 11−4.1%370% | 12+24.9%409% | 14+51.8%327% | 42*+495%984% | 12—307% | 9.4—849% | 9.4—550% | 7.1*—421% | |
| Operating income | −62—−778% | −19—−1693% | −16—−2183% | −14—−666% | −11*—−296% | −8.3—−270% | −8.9—−309% | −9.9—−227% | −38*—−884% | −8.0—−207% | −8.3—−749% | −7.7—−450% | −5.4*—−321% | |
| Interest expense and finance costs | 0.3+316%3.6% | 0.1*+16.2%6.9% | 0.1*—9.8% | 0.1—3.2% | 0.1*—1.6% | 0.1—2.2% | 0*—0.0% | 0—0.0% | 0*—0.0% | 0—0.0% | — | — | 0*—0.0% | |
| Other non-operating income (expense) | 4.7+16.7%59.6% | 1.4+257%120% | 1.7+226%230% | 0.8+179%39.1% | 0.8r0.7*−72.7%19.9% | 0.4r0.5−20.9%12.4% | 0.5−5.2%18.5% | 0.3−49.8%6.9% | 2.8*+360%65.6% | 0.5—12.5% | 0.6—50.6% | 0.6—35.2% | 0.6*—36.3% | |
| Income before tax | −137—−1727% | −46—−4089% | −8.1—−1073% | −66—−3038% | −17*—−428% | −17—−567% | −7.4—−257% | −8.2—−188% | −35*—−817% | −7.5—−195% | −7.8—−698% | −7.1—−415% | −4.8*—−284% | |
| Income tax | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0*—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0*—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | −0.0*—−0.1% | |
| Net income attributable to shareholders | −137—−1727% | −46—−4089% | −8.1—−1073% | −66—−3038% | −17*—−428% | −17—−567% | −7.4—−257% | −8.2—−188% | −35*—−817% | −7.5—−195% | −7.8—−698% | −7.1—−415% | −4.8*—−284% | |
| Earnings per share, basic | — | -0.46—— | -0.08—— | -0.75—— | — | -0.25—— | -0.12—— | -0.24—— | — | -0.29—— | -0.30—— | -0.29—— | — | |
| Earnings per share, diluted | — | -0.46—— | -0.14—— | -0.75—— | — | -0.25—— | -0.12—— | -0.24—— | — | -0.29—— | -0.30—— | -0.29—— | — | |
| Shares, weighted average (basic) | 102+44.2%— | 102+44.2%— | 95+50.7%— | 87+156%— | — | 71+170%— | 63+145%— | 34+38.2%— | — | 26—— | 26—— | 25—— | — | |
| Shares, weighted average (diluted) | 102+44.2%— | 102+44.2%— | 111+75.8%— | 87+156%— | — | 71+170%— | 63+145%— | 34+38.2%— | — | 26—— | 26—— | 25—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 89—93.4% | 89+189%93.4% | 89+174%95.5% | 60+43.5%89.8% | 45+48.7%89.7% | 31−15.9%85.3% | 32−21.7%83.9% | 42−11.4%86.8% | 30−40.0%82.3% | 37—90.7% | 41—92.4% | 47—91.0% | 51—93.6% | |
| Short-term investments | — | — | — | — | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0.0−80.0%0.0% | 0.0−86.7%0.0% | 0.0—0.0% | 0.0—0.0% | 0.0—0.0% | 0.0—0.0% | |
| Receivables | 1.0—1.1% | 1.0−65.5%1.1% | 1.0−69.4%1.1% | 1.7−43.8%2.6% | 2.0−44.0%4.0% | 2.9+57.0%8.1% | 3.4+150%8.8% | 3.1+60.1%6.4% | 3.6+285%9.7% | 1.9—4.6% | 1.4—3.0% | 1.9—3.7% | 0.9—1.7% | |
| Other current assets | 4.2—4.5% | 4.2+421%4.5% | 2.4+69.4%2.6% | 3.9+185%5.9% | 1.8+247%3.6% | 0.8+848%2.3% | 1.4+1547%3.7% | 1.4+1451%2.9% | 0.5+405%1.4% | 0.1—0.2% | 0.1—0.2% | 0.1—0.2% | 0.1—0.2% | |
| Current assets | 95—99.5% | 95+164%99.5% | 93+141%99.7% | 67+39.0%99.7% | 50+36.7%99.6% | 36−11.1%99.4% | 38−14.3%99.4% | 48−7.6%99.5% | 37−32.1%99.3% | 40—100% | 45—100% | 52—100% | 54—100% | |
| Property, plant and equipment | 0.3—0.4% | 0.3+59.9%0.4% | 0.2−23.9%0.2% | 0.2−22.2%0.3% | 0.2−21.0%0.4% | 0.2—0.6% | 0.2—0.6% | 0.2—0.5% | 0.3—0.7% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | |
| Total assets | 95—100% | 95+164%100% | 93+140%100% | 67+38.7%100% | 50+36.3%100% | 36−10.6%100% | 39−13.8%100% | 48−7.1%100% | 37−31.7%100% | 40—100% | 45—100% | 52—100% | 54—100% | |
| Accounts payable | 3.7—3.9% | 3.7+55.6%3.9% | 1.9+28.4%2.0% | 4.4+82.0%6.6% | 3.3+4.6%6.6% | 2.4+184%6.6% | 1.5+131%3.8% | 2.4+17.7%5.0% | 3.1+46.2%8.5% | 0.8—2.1% | 0.6—1.4% | 2.1—4.0% | 2.2—4.0% | |
| Current liabilities | 9.8—10.3% | 9.8−66.2%10.3% | 7.6−62.3%8.2% | 9.3−61.5%14.0% | 7.8−31.1%15.5% | 29+378%80.5% | 20+381%52.2% | 24+319%50.3% | 11+179%30.6% | 6.1—15.1% | 4.2—9.4% | 5.8—11.2% | 4.0—7.5% | |
| Long-term debt | — | — | — | 1.2—1.8% | 1.1—2.2% | 1.1—3.0% | 1.0—2.6% | — | 0—0.0% | — | — | — | — | |
| Total liabilities | 57—59.7% | 57+88.6%59.7% | 106+400%114% | 88+262%132% | 35+209%69.5% | 30+395%83.5% | 21+405%54.8% | 24+319%50.3% | 11+179%30.6% | 6.1—15.1% | 4.2—9.4% | 5.8—11.2% | 4.0—7.5% | |
| Retained earnings | −309—−324% | −309—−324% | −262—−282% | −254—−380% | −189—−375% | −172—−476% | −155—−400% | −147—−306% | −139—−377% | −104—−257% | −96—−215% | −89—−171% | −81—−151% | |
| Shareholders' equity | 38—40.3% | 38+544%40.3% | −13−174%−14.0% | −46−1004%−68.6% | 15+128%30.5% | 6.0−82.6%16.5% | 17−57.0%45.2% | 5.1−89.0%10.5% | 6.7−86.5%18.2% | 34—84.9% | 41—90.6% | 46—88.8% | 50—92.5% | |
| Total liabilities and equity | 95—100% | 95+164%100% | 93+140%100% | 67+38.7%100% | 50+36.3%100% | 36−10.6%100% | 39−13.8%100% | 48−7.1%100% | 37−31.7%100% | 40—100% | 45—100% | 52—100% | 54—100% | |
| Shares outstanding | 96—— | 96+48.4%— | 83+38.0%— | 71+57.0%— | 70+121%— | 65+146%— | 60+131%— | 45+81.3%— | 32+31.7%— | 26—— | 26—— | 25—— | 24—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 5.2+53.1%66.1% | 1.6+94.9%140% | 1.4+57.0%186% | 1.5+60.4%67.9% | 0.8*−2.6%20.0% | 0.8+5.2%26.5% | 0.9+11.2%31.1% | 0.9−7.3%20.9% | 0.8*+11.8%18.5% | 0.8—20.1% | 0.8—72.5% | 1.0—57.6% | 0.7*—42.0% | |
| Cash from operating activities | −49—−613% | −14*—−1234% | −12*—−1583% | −13—−590% | −9.8*—−254% | −6.2*—−200% | −10*—−356% | −9.0—−206% | −7.4*−264%−173% | −5.1*—−133% | −7.3*—−656% | −5.7—−334% | 4.5*—269% | |
| Cash from investing activities | −0.2−116%−2.4% | −0.2*—−16.6% | 0*—0.0% | 0—0.0% | 0*−100%0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | 1.2*—28.1% | 0*—0.0% | 0*—0.0% | 0—0.0% | 0*—0.0% | |
| Debt issued | — | 0*—0.0% | — | — | — | 0*—0.0% | — | — | — | — | — | — | — | |
| Shares issued | 2.4−56.8%30.7% | 0*−100%0.0% | 0*—0.0% | 2.3+450%104% | 0.2*—4.6% | 5.2*+1044%169% | 0*−100%0.0% | 0.4−83.5%9.4% | 0*−100%0.0% | 0.5*—11.8% | 1.6*—140% | 2.5—145% | 3.7*—221% | |
| Cash from financing activities | 107+314%1352% | 14*+217%1265% | 41*+4415%5418% | 28+34.8%1279% | 24*—624% | 4.5*+1187%148% | 0.9*−41.2%31.4% | 20+761%468% | −0.1*−102%−1.9% | 0.4*—9.1% | 1.5*—138% | 2.4—139% | 3.6*—213% | |
| Change in cash | — | 0.2*—14.2% | 29*—3835% | 15+29.6%689% | — | −1.6*—−52.4% | −9.4*—−325% | 11—262% | — | — | — | — | — | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Opus Genetics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Dr. McGrath | $1.5 M | $2.5 M | $742 K | $57 |
| 2024Dr. McGrath | $889 K | −$822 K | $1.3 M | $34 |
| 2023Chief executive | $2.8 M | $766 K | $894 K | $85 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Opus Genetics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 4 · Material agreement 5 · New debt 1 · Unregistered share sale 3 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 8
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| New debt | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share saleBylaws or fiscal year changedResults announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Unregistered share sale | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Government contracts: Opus Genetics, Inc.#
No federal contracts in fiscal 2025, and $837 K in grants.
| Fiscal year | Contracts | Grants |
|---|---|---|
| FY2025 | $0 | $837 K |
| FY2024 | $0 | $883 K |
Source: USAspending.gov. Obligations are binding promises to pay, not payments, and can be negative when an award is cut. Counted under Opus Genetics, Inc.: OPUS GENETICS INC. (UEI YD2GB4S983V9)
Lobbying by Opus Genetics, Inc.#
$0 spent on lobbying the US Congress and federal agencies in 2025.
Lobbying firms hired in 2025
JEFFREY J. KIMBELL & ASSOCIATES, INC.
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $45 K | — | 3 |
| 2025 | $0 | — | 1 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Opus Genetics, Inc”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
How Opus Genetics, Inc. compares in Biotechnology
- Market cap$396 M · higher than 55% of 726
- Revenue$14 M · higher than 47% of 647
- Revenue growth29.2% · higher than 66% of 438
- Price / sales50.0× · lower than 18% of 339
- Price / book25.8× · lower than 7% of 534
- FCF yield-1.7% · higher than 83% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Opus Genetics, Inc.🇺🇸 | $396 M | — | — | +29.2% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 15, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Opus Genetics, Inc.? Verify and update this profile — free
Show Opus Genetics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.